Oxytocin Pharmacokinetics and Pharmacodynamics

Launched by UNIVERSITY OF CHICAGO · Aug 2, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of oxytocin, a medication commonly used after childbirth to help the uterus contract and prevent excessive bleeding. The trial will look at how oxytocin works in women who have a cesarean delivery, focusing on how the drug is processed in the body (pharmacokinetics) and how well it performs its job of contracting the uterus (pharmacodynamics). By understanding these details, researchers hope to improve treatment for women who experience complications from uterine atony, a condition where the uterus doesn't contract as it should.

To participate in the study, women must be between 18 and 50 years old, be in the late stages of pregnancy (at least 37 weeks), and have a non-emergency scheduled or unscheduled cesarean section. Participants will receive an intravenous (IV) dose of a special form of oxytocin right after delivery and will have their blood drawn several times to measure how the drug works over time. This information will help researchers identify why some women do not respond well to oxytocin treatment. If you’re considering participating, it’s important to know that you cannot join if you have an allergy to oxytocin or cannot give informed consent.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria
• • 18-50 years old
• • intrauterine pregnancy
• • term (\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy
• • non-emergent (scheduled or unscheduled) cesarean delivery
• Exclusion Criteria:
• • allergy or contraindication to oxytocin
• • inability to provide informed consent